Health News Roundup: Israel's, FDA nod to treat tumors in the liver, kidney; Verdict in Bayer's Roundup case should be reversed (U.S.) and more

Following is a summary of current health news briefs.

Israel's IceCure says gets FDA nod to treat tumors in the liver, kidney

Israel's IceCure Medical said on Sunday it received U.S. regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumors in livers and kidneys, sending its share price up 30%. IceCure's treatment uses special needles to inject liquid nitrogen to freeze and destroy tumors without the need for surgery.

U.S. government says verdict in Bayer's Roundup case should be reversed

The U.S. Environmental Protection Agency and the Justice Department said a federal appeals court should reverse a lower court verdict finding Bayer AG liable in the case of a California man who blamed its Roundup weed killer for his cancer. The government said in a friend of the court brief filed on Friday that glyphosate, the weed killer's active ingredient, is not a carcinogen and as a result a warning on the label was not required as California state law demands.

AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA

The U.S. Food and Drug Administration said on Friday it had approved Daiichi Sankyo Co Ltd and AstraZeneca Plc's drug to treat an advanced form of breast cancer, three months ahead of schedule. AstraZeneca in March signed a licensing and collaboration deal that committed the British drugmaker to pay up to $6.9 billion to its Japanese partner Daiichi. (https://reut.rs/2sKMyIy)

U.S. FDA declines to approve GSK drugs division's long-acting HIV injection

GlaxoSmithKline's HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long-acting HIV injection. ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment's chemistry, manufacturing and controls process, but not its safety.

Merck says Ebola vaccine to be available at lowest access price for poor nations

Merck & Co said on Friday it expects to make licensed doses of its recently approved Ebola vaccine available in the third quarter of 2020 and price the single-dose injection at the lowest possible access price for poor and middle-income countries. The vaccine, Ervebo, was approved by the U.S. Food and Drug Administration on Thursday, a month after Europe gave its nod to the vaccine, a move that has been hailed by the World Health Organization.